Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in advanced neuroendocrine tumors
NCT03167853Phase 1Completed
- Sponsor
- Peking University
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in Neuroendocrine Neoplasm (NEN), sponsored by Peking University. Primary endpoint: Overall Response Rate up to 24 months. Started Apr 2017; status: completed.
02
Drugs
toripalimab
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03167853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167853.